Home » NEWS » Health » Hawthorn Pharmaceuticals cuts global deal with CoPlex

Hawthorn Pharmaceuticals cuts global deal with CoPlex

MADISON — Hawthorn Pharmaceuticals Inc. has struck an exclusive global licensing deal with CoPlex Therapeutics on hawAD14, a preclinical oral small molecule candidate for the treatment of Alzheimer’s and other neurodegenerative diseases.

Under the terms of the agreement, Hawthorn will receive an exclusive worldwide license to develop and commercialize hawAD14 and will be responsible for funding all future development.

“In terms of the discovery’s uniqueness, it’s one of only few programs in the world demonstrating multiple protective effects against the predominant pathophysiologic pathways of Alzheimer’s disease,” said Rob Lewis, chief scientific officer at Hawthorn Pharmaceuticals.

“We are in the process of conducting the necessary preclinical studies in order to file an IND with the FDA,” said Max Draughn, Hawthorn Pharmaceuticals’ CEO.


… we’d like to ask for your support. More people are reading the Mississippi Business Journal than ever before, but advertising revenues for all conventional media are falling fast. Unlike many, we do not use a pay wall, because we want to continue providing Mississippi’s most comprehensive business news each and every day. But that takes time, money and hard work. We do it because it is important to us … and equally important to you, if you value the flow of trustworthy news and information which have always kept America strong and free for more than 200 years.

If those who read our content will help fund it, we can continue to bring you the very best in news and information. Please consider joining us as a valued member, or if you prefer, make a one-time contribution.

Click for more info

About MBJ Staff

Leave a Reply